Mauna Kea touts data from Cellvizio lung transplant study

This study provides further evidence of the broad potential of the Cellvizio platform to improve diagnostic and treatment outcomes. We thank Dr. Keller and his colleagues for conducting this unique study sponsored by Mauna Kea Technologies and demonstrating that with proper training, the procedure is effective and reproducible. We are optimistic that Cellvizio will increasingly be used in a variety of applications that can benefit from its unique ability to provide real-time diagnostic information at the cellular level. Moreover, image interpretation automation with artificial intelligence will contribute to the performance and adoption of Cellvizio in this and other applications,” CEO &founder Sacha Loiseau said in a press release. Earlier this month, Mauna Kea said it won 510(k) clearance from the FDA for its Confocal miniprobes designed for use with the company’s Cellvizio platform. The Confocal miniprobes are indicated for use in urological and minimally invasive surgical applications along with the near-infared Cellvizio platform. The post Mauna Kea touts data from Cellvizio lung transplant study appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Imaging Mauna Kea Technologies Source Type: news

Related Links:

Voriconazole exposure and longer duration of voriconazole were found to be significantly associated with increased risk of squamous cell carcinoma. Regular dermatologic surveillance should be considered for the patients taking voriconazole, especially those at high risk of developing squamous cell carcinoma.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Transplant Infectious Disease,Volume 0, Issue ja, -Not available-.
Source: Transplant Infectious Disease - Category: Transplant Surgery Authors: Source Type: research
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Condition:   Respiratory Insufficiency Intervention:   Other: Questionnaire BPI Sponsor:   Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Disorder;   Frail Elderly Syndrome;   Sarcopenia;   Lung Graft Dysfunction;   Mobility Limitation Intervention:   Other: Ambulation Sponsor:   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Respiratory Insufficiency Intervention:   Other: Questionnaire BPI Sponsor:   Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Disorder;   Frail Elderly Syndrome;   Sarcopenia;   Lung Graft Dysfunction;   Mobility Limitation Intervention:   Other: Ambulation Sponsor:   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The diagnostic criteria for antibody-mediated rejection (AMR) after lung transplantation (LTx) includes immunohistochemistry (IHC) staining patterns for C4d but not C3d.1 Historically, C3d deposition is a recognized complication after LTx associated with primary graft dysfunction and early bronchiolitis obliterans syndrome (BOS)2,3 but is not widely used in LTx even though it's a result of complement deposition via the classical pathway.4 The International Society for Heart and Lung Transplantation Pathology Council established a threshold of>50% deposition of C4d in interstitial capillaries as diagnostic but emphasized...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
Lung donor utilization rates remain low with many organs refused for donor quality. However, certain centers have successfully transplanted these organs despite multiple refusals for donor quality (RDQ) by other centers. We hypothesize that the number of refusals due to donor quality does not impact post-transplant outcomes.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Significant right ventricular failure accompanying left ventricular failure was treated by implantation of the fully magnetically levitated centrifugal HeartMate 3 ventricular assist device as bi-ventricular support in 14 patients in 6 medical centers worldwide. The clinical details of this first multi-center experience are described, with 9 of these patients (64%) being alive as of January 1, 2018 - 8 of them ongoing on BiVAD support for 95 - 636 (mean 266) days, 7 of them at home, and one successfully transplanted after 98 days of support.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Innovation Source Type: research
More News: Clinical Trials | Conferences | Lung Transplant | Study | Training | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology